In this Issue
The Future of Retina and the Latest Data
Medical Editors’ Page
By Allen C. Ho, MD; and Robert L. Avery, MD
By Kumar Saurabh, MD, MS; and Rupak Roy, MD, MS
Although this rare occurrence is not harmful, patients and clinicians should be educated on the potential sequelae following anti-VEGF treatment.
By Eric K. Chin, MD; and David R.P. Almeida, MD, MBA, PhD
Choroidal metastasis is rare in individuals with renal cancer.
By Jordana G. Fein, MD, MS; Heeral R. Shah, MD; Komal B. Desai, MD; Taylor Lind; and Uma Desai
This review will help you understand where several potentially important studies stand.
By Michael Ammar, MD; and Jason Hsu, MD
By moving beyond thinking of the pipeline as which drug is in which phase, we can take a fresh perspective on therapeutic candidates in development.
By Pravin U. Dugel, MD
What might the future of wet AMD therapy look like?
By Priyatham (Prithu) S. Mettu, MD
In a symposium ahead of the AAO Annual Meeting, speakers updated attendees on the status of the field.
By Kourous A. Rezaei, MD
Take a look at what’s next in uveitis.
With Steven Yeh, MD
Products in the pipeline could improve outcomes and reduce burdens on patients and physicians.
By John B. Miller, MD; and Rebecca Zeng, BA; With Sidebar Commentary by Judy E. Kim, MD
A dose-dependent increase in protein expression was noted in interim results, with lasting effect in higher doses.
By Jeffrey S. Heier, MD; Allen C. Ho, MD; and Robert L. Avery, MD
An update on ADVM-022 and the OPTIC trial.
By Szilárd Kiss, MD
By Yale L. Fisher, MD; and Hugo Quiroz-Mercado, MD; Summarized by Luis A. Gonzalez, MD, MPH
A lecture by Stephen Tsang, MD, PhD, explored progress in this burgeoning field.